Adherence Improvement in Glaucoma Patients

This study has been completed.
Sponsor:
Collaborator:
Alcon Laboratories
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT00603005
First received: January 15, 2008
Last updated: February 23, 2010
Last verified: February 2010

January 15, 2008
February 23, 2010
October 2007
October 2009   (final data collection date for primary outcome measure)
Intraocular pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00603005 on ClinicalTrials.gov Archive Site
Information with regard to the use of eye drops from data generated by the TravAlert dosing system [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Adherence Improvement in Glaucoma Patients
Adherence Improvement in Glaucoma Patients

The purpose of this study is to study the effect on intraocular pressure in glaucoma patients using the TravAlert dosing aid with or without the Eyot drop guider and with or without additional patient education.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single Blind (Caregiver)
Primary Purpose: Supportive Care
Glaucoma
Device: Use of TravAlert dosing aid with or without drop guider
Each patient will use a dosing aid and/or drop guider for 6 months
  • Experimental: 1
    Intervention: Device: Use of TravAlert dosing aid with or without drop guider
  • Experimental: 2
    Intervention: Device: Use of TravAlert dosing aid with or without drop guider
  • Experimental: 3
    Intervention: Device: Use of TravAlert dosing aid with or without drop guider
  • Experimental: 4
    Intervention: Device: Use of TravAlert dosing aid with or without drop guider
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
802
January 2010
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis glaucoma or ocular hypertension
  • Treatment with travoprost or travoprost/timolol

Exclusion Criteria:

  • High risk of side effects expected from travoprost or travoprost/timolol
  • Absolute inability to administer eye drops
  • Difficulty in reading or speaking Dutch
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00603005
MEC 07-1-015, CTCM-071015
Yes
Dr. H.J.M. Beckers, MD, phD, Department of Ophthalmology, University Hospital Maastricht
Maastricht University Medical Center
Alcon Laboratories
Principal Investigator: Helena J Beckers, MD/phD Maastricht University Medical Center
Maastricht University Medical Center
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP